CytoMed Therapeutics Limited Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital
CytoMed Therapeutics Limited (GDTC) reported Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital of -SGD 3.21 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes
ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital · last filed 2026-03-31
SGD
| Period end | Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital 12 month |
|---|---|
| 2025-12-31 | -3.21M SGD 20-F · filed 2026-03-31 |
| 2024-12-31 | -2.65M SGD 20-F · filed 2026-03-31 |
| 2023-12-31 | -3.63M SGD 20-F · filed 2026-03-31 |
| 2022-12-31 | -1.51M SGD 20-F · filed 2025-04-28 |
| 2021-12-31 | -1.35M SGD 20-F · filed 2024-04-22 |
| 2020-12-31 | -965.03K SGD 20-F · filed 2023-05-01 |
USD
| Period end | Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital 12 month |
|---|---|
| 2025-12-31 | -$2.50M 20-F · filed 2026-03-31 |
| 2024-12-31 | -$1.94M 20-F · filed 2025-04-28 |
| 2023-12-31 | -$2.75M 20-F · filed 2024-04-22 |
| 2022-12-31 | -$1.13M 20-F · filed 2023-05-01 |